(Q38037149)

27 August 2017

Analytical aspects of molecular Alzheimer's disease biomarkers (English)

1 reference

27 August 2017

0 references

0 references

2

1 reference

27 August 2017

4

Henrik Zetterberg

1 reference

27 August 2017

1

Ulf Andreasson

1 reference

27 August 2017

5

Hugo Vanderstichele

1 reference

27 August 2017

Leslie M Shaw

3

1 reference

27 August 2017

1 August 2012

1 reference

27 August 2017

Biomarkers in Medicine

1 reference

27 August 2017

6

1 reference

27 August 2017

4

1 reference

27 August 2017

377-389

1 reference

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

27 August 2017

1 reference

Biomarkers and surrogate markers: an FDA perspective

21 January 2018

1 reference

Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report.

21 January 2018

1 reference

Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42.

21 January 2018

1 reference

Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics

21 January 2018

1 reference

New diagnostic criteria for Alzheimer's disease.

21 January 2018

1 reference

The clinical use of structural MRI in Alzheimer disease

21 January 2018

1 reference

Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications

21 January 2018

1 reference

Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden--regulatory considerations by European Medicines Agency focusing in improving be

21 January 2018

1 reference

Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein

21 January 2018

1 reference

Amyloid plaque core protein in Alzheimer disease and Down syndrome

21 January 2018

1 reference

The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor

21 January 2018

1 reference

Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids

21 January 2018

1 reference

Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid.

21 January 2018

1 reference

Concentrations of amyloid beta protein in cerebrospinal fluid of patients with Alzheimer's disease.

21 January 2018

1 reference

Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry

21 January 2018

1 reference

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

21 January 2018

1 reference

Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach

21 January 2018

1 reference

A protein factor essential for microtubule assembly

21 January 2018

1 reference

Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology

21 January 2018

1 reference

Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay.

21 January 2018

1 reference

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

21 January 2018

1 reference

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

21 January 2018

1 reference

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

21 January 2018

1 reference

Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies.

21 January 2018

1 reference

Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process

21 January 2018

1 reference

The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers

21 January 2018

1 reference

Cerebrospinal fluid protein biomarkers for Alzheimer's disease

21 January 2018

1 reference

Both total and phosphorylated tau are increased in Alzheimer's disease

21 January 2018

1 reference

Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.

21 January 2018

1 reference

Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment

21 January 2018

1 reference

Screening for new biomarkers for subcortical vascular dementia and Alzheimer's disease

21 January 2018

1 reference

Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins

21 January 2018

1 reference

A serum protein-based algorithm for the detection of Alzheimer disease

21 January 2018

1 reference

Toward an Alzheimer's disease diagnosis via high-resolution blood gene expression

21 January 2018

1 reference

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

21 January 2018

1 reference

Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease.

21 January 2018

1 reference

Enzyme-linked immunosorbent assay (ELISA) quantitative assay of immunoglobulin G

21 January 2018

1 reference

Immunoassay using antigen-enzyme conjugates.

21 January 2018

1 reference

Electrogenerated chemiluminescence

21 January 2018

1 reference

An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid

21 January 2018

1 reference

Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry

21 January 2018

1 reference

Analysis of amyloid-β peptides in cerebrospinal fluid samples by capillary electrophoresis coupled with LIF detection

21 January 2018

1 reference

Quantitation of amyloid beta peptides Aβ(1-38), Aβ(1-40), and Aβ(1-42) in human cerebrospinal fluid by ultra-performance liquid chromatography-tandem mass spectrometry.

21 January 2018

1 reference

Characterization of tau in cerebrospinal fluid using mass spectrometry.

21 January 2018

1 reference

Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma.

21 January 2018

1 reference

Non-linear relationships of cerebrospinal fluid biomarker levels with cognitive function: an observational study

21 January 2018

1 reference

Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

21 January 2018

1 reference

Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative

21 January 2018

1 reference

Cerebrospinal fluid collection tubes: a critical issue for Alzheimer disease diagnosis.

21 January 2018

1 reference

Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease” 11The names of the Working Group Members and the names of the Working Group Advisory Committee Members are listed in the Appendix A(section VI)

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/BMM.12.44

1 reference

27 August 2017

1 reference

PubMed ID

22917140